The FDA recently announced it will update labels for fluoroquinolone antibiotics to increase warnings about the risks of associated adverse mental health effects and serious blood sugar disturbances. The agency is stating that the updates aim to make the warnings more consistent across all labels for fluoroquinolone that are taken orally or injected. This class of antibiotics are commonly used to treat serious bacterial infections. Read the FDA news release for more information. Antibiotics should be used judiciously and appropriately to reduce adverse events and resistance. For more on antibiotic stewardship, contact Meg Kilcup. (Meg Kilcup)
Contact Us
Washington State Hospital Association
999 Third Avenue
Suite 1400
Seattle, WA 98104